IL286870A - Hexahydro-h1-pyrazino[a-2,1]pyrazine compounds for the treatment of autoimmune disease - Google Patents

Hexahydro-h1-pyrazino[a-2,1]pyrazine compounds for the treatment of autoimmune disease

Info

Publication number
IL286870A
IL286870A IL286870A IL28687021A IL286870A IL 286870 A IL286870 A IL 286870A IL 286870 A IL286870 A IL 286870A IL 28687021 A IL28687021 A IL 28687021A IL 286870 A IL286870 A IL 286870A
Authority
IL
Israel
Prior art keywords
pyrazino
hexahydro
treatment
autoimmune disease
pyrazine compounds
Prior art date
Application number
IL286870A
Other languages
English (en)
Hebrew (he)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL286870A publication Critical patent/IL286870A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL286870A 2019-04-09 2021-09-30 Hexahydro-h1-pyrazino[a-2,1]pyrazine compounds for the treatment of autoimmune disease IL286870A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2019081900 2019-04-09
CN2019121598 2019-11-28
CN2020078225 2020-03-06
PCT/EP2020/059831 WO2020207991A1 (en) 2019-04-09 2020-04-07 Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease

Publications (1)

Publication Number Publication Date
IL286870A true IL286870A (en) 2021-10-31

Family

ID=70228042

Family Applications (1)

Application Number Title Priority Date Filing Date
IL286870A IL286870A (en) 2019-04-09 2021-09-30 Hexahydro-h1-pyrazino[a-2,1]pyrazine compounds for the treatment of autoimmune disease

Country Status (19)

Country Link
US (1) US20220340597A1 (cg-RX-API-DMAC10.html)
EP (1) EP3953356B1 (cg-RX-API-DMAC10.html)
JP (1) JP7692838B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210149163A (cg-RX-API-DMAC10.html)
CN (1) CN113710672B (cg-RX-API-DMAC10.html)
AU (1) AU2020272467A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021020297A2 (cg-RX-API-DMAC10.html)
CA (1) CA3135129A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021002621A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021013166A2 (cg-RX-API-DMAC10.html)
CR (1) CR20210513A (cg-RX-API-DMAC10.html)
IL (1) IL286870A (cg-RX-API-DMAC10.html)
MA (1) MA55594A (cg-RX-API-DMAC10.html)
MX (1) MX2021012223A (cg-RX-API-DMAC10.html)
PE (1) PE20212178A1 (cg-RX-API-DMAC10.html)
PH (1) PH12021552533A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202110401WA (cg-RX-API-DMAC10.html)
TW (1) TW202104230A (cg-RX-API-DMAC10.html)
WO (1) WO2020207991A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114599652B (zh) * 2019-10-31 2024-07-12 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢吡嗪并[1,2-d][1,4]二氮杂䓬化合物
WO2021094301A1 (en) * 2019-11-12 2021-05-20 F. Hoffmann-La Roche Ag Hydropyrazino[1,2-b]isoquinoline compounds for the treatment of autoimmune disease
EP4061816A1 (en) 2019-11-19 2022-09-28 F. Hoffmann-La Roche AG Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease
US12503471B2 (en) 2019-11-19 2025-12-23 Hoffmann-La Roche Inc. Triazatricycle compounds for the treatment of autoimmune disease
US12478621B2 (en) 2019-11-28 2025-11-25 Deutsches Krebsforschungszentrum Substituted aminoquinolones as dgkalpha inhibitors for immune activation
CN114761406B (zh) 2019-12-03 2024-04-19 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢吡啶并[1,2-a]吡嗪化合物
JP2023533807A (ja) * 2020-07-14 2023-08-04 エフ. ホフマン-ラ ロシュ アーゲー 自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2663555T3 (en) * 2011-01-12 2017-03-27 Ventirx Pharmaceuticals Inc SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
HRP20171981T1 (hr) 2012-09-14 2018-02-09 F. Hoffmann - La Roche Ag Derivati pirazolkarboksamida kao taar modulatora za uporabu u liječenju nekoliko poremećaja poput depresije, dijabetesa i parkinsonove bolesti
US9643967B2 (en) * 2013-12-13 2017-05-09 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors
MX2021006804A (es) 2015-12-17 2023-01-13 Merck Patent Gmbh Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
JP2021527100A (ja) * 2018-06-13 2021-10-11 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 自己免疫疾患の処置のためのピリジニルヘテロシクリル化合物
CN112752755A (zh) * 2018-09-27 2021-05-04 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的杂环基化合物

Also Published As

Publication number Publication date
AU2020272467A1 (en) 2021-10-14
WO2020207991A1 (en) 2020-10-15
PH12021552533A1 (en) 2022-06-20
PE20212178A1 (es) 2021-11-09
EP3953356C0 (en) 2023-07-26
EP3953356B1 (en) 2023-07-26
CO2021013166A2 (es) 2021-12-10
SG11202110401WA (en) 2021-10-28
BR112021020297A2 (pt) 2021-12-14
CN113710672A (zh) 2021-11-26
EP3953356A1 (en) 2022-02-16
JP7692838B2 (ja) 2025-06-16
CN113710672B (zh) 2025-01-03
MA55594A (fr) 2022-02-16
CR20210513A (es) 2021-11-02
MX2021012223A (es) 2021-11-03
CA3135129A1 (en) 2020-10-15
TW202104230A (zh) 2021-02-01
KR20210149163A (ko) 2021-12-08
JP2022527588A (ja) 2022-06-02
CL2021002621A1 (es) 2022-05-13
US20220340597A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
IL279144A (en) Tetrahydro-1H-pyrazino[2,1-azisoindolylquinoline compounds for the treatment of immune system disease
IL285782A (en) Compounds, compositions, and methods for the treatment of disease
IL269599A (en) 11,13-modified saxitoxins for the treatment of pain
EP3980010A4 (en) 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS
IL270134B (en) A process for the preparation of compounds 3,2-dihydrothiazolo[2,3-a]pyrimidine-4-threat optical activity
PL3838274T3 (pl) Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
HK1247203A1 (zh) 取代的咪唑并[1,2-α]吡啶-2-基胺化合物及其药物组合物和使用方法
SG10202110927VA (en) Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid
EP3744723A4 (en) SUBSTITUTED MACROCYCLIC PYRAZOLO [1,5-A] PYRIMIDINE COMPOUND
IL235659A0 (en) History of 3, 4 - dihydro -2h - pyrido [1, 2 - a] pyrazine - 1,2,1] 6 converted diones used to treat (among others) Alzheimer's disease
IL267801B1 (en) Process for the preparation of 3-disubstituted 5-amino-h6-thiazolo[5,4-d]pyrimidine-7,2-dione compounds
EP3709998B8 (en) N-[5-(imidazo[1,2-a]pyrimidin-2-yl)phenyl]-benzamide and -benzeneacetamide derivatives as tnf stimulators for the treatment of e.g. infectious diseases and cancer
SG10201810660QA (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
IL276482A (en) Compounds for pain management
IL272988A (en) Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors
IL287887A (en) Synthesis of labeled imidazo[2,1-a]pyrimidines
IL291640A (en) Compounds of 1,8-naphthyridin-2-one for the treatment of autoimmune disease
HUE069820T2 (hu) Nalfurafin alkalmazása demielinizációs betegségek kezelésére
PL3277687T3 (pl) Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-a]pirymidyny użyteczne do leczenia chorób immunologicznych lub zapalnych lub nowotworów
PL3599243T3 (pl) Związki podobne do 17beta-heterocyklilu naparstnicy do leczenia niewydolności serca
IL288234A (en) Compounds for the treatment of neuromuscular disorders
EP4069693C0 (en) HYDROPYRIDO[1,2-ALPHA]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
IL310443A (en) PYRAZOLO[3,4-B]PYRIDINE compounds for the treatment of autoimmune disease
IL278935B2 (en) Piazolo[e-3,4]pyrimidine compounds are being modified for use in cancer treatment
ZA202400834B (en) Pyrazolo[3,4-b]pyridine compounds for the treatment of autoimmune disease